EGFRT790M rare mutation high-sensitive extraction-free test kit

Abstract

The invention relates to the field of tumor cell detection, in particular to a high-sensitive extraction-free kit used for detecting EGFR T790M rare mutation from human peripheral blood CTC. The kit particularly comprises T790M detection reagent, a reference gene detection reagent, a 790 M positive and negative quality control materials and the like. Preferably, a reference gene actin beta gene and a mutant gene are T790M positive quality control materials, and a T790M negative quality control material is process water. An operation method comprises the steps of CTC negative enrichment, PCR amplification, result judgement and the like. The kit has the advantages that according to the technical scheme, a test sample is blood, no genome extraction technology is needed, substrate loss causedby sample extraction is effectively avoided, and the kit is suitable for different stages of cancer patients, and comprises but not limited to early stage, middle stage, late stage, pre-operation andpostoperation therapeutic detection, recurrence detection and the like.

Description

technical field [0001] The invention relates to the field of tumor cell detection, in particular to a highly sensitive extraction-free kit for detecting rare mutations of EGFRT790M from human peripheral blood CTCs. Background technique [0002] Lung cancer is a malignant tumor with the highest morbidity and mortality rate in the world. Due to the diversity of lung cancer pathogenesis and the limitations of treatment monitoring tools, most patients often cannot benefit from clinical treatment. For example, the disease response rate of chemotherapy for lung cancer is only 15% to 20%. [0003] Large-scale clinical trials have confirmed that targeted drugs represented by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have significant curative effects on patients with EGFR-mutated non-small cell lung cancer and can prolong their disease-free Progression survival and overall survival. However, patients who are clinically effective for TKI drugs will d...

AI Technical Summary

Problems solved by technology

The sensitivity of the sequencing method is about 20% lower, and the operation is complicated and the detection time is longer

The ARMS-PCR method can achieve a sensitivity of 1%, which can still meet the detection requirements for tumor tissue samples with a high mutation rate, but it is difficult to effectively detect tissue samples with low mutation content, especially blood samples.

Images